Oculis Holding AG (NASDAQ:OCS) Given Consensus Rating of "Moderate Buy" by Analysts

Key Points

• Analyst sentiment is moderately bullish: Oculis has a consensus “Moderate Buy” rating, with nine buy ratings and one sell rating among 10 analysts. The average 12-month price target is $39.44.
• Price targets have been lowered: Needham, Robert W. Baird, JPMorgan, and Stifel recently reduced their targets, though each maintained a positive rating on the stock.
• Oculis remains an early-stage, loss-making biotech: Shares opened at $9.98, near the company’s 12-month low of $9.65, while the latest quarter showed a $0.20 loss per share and only $0.38 million in revenue. The company is developing ophthalmic therapies, including the OCS-01 eye-drop treatment.

Oculis Holding AG (NASDAQ:OCS - Get Free Report) has received an average rating of "Moderate Buy" from the ten analysts that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and nine have issued a buy rating on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $39.4444.

A number of research firms have weighed in on OCS. Wall Street Zen raised Oculis from a "strong sell" rating to a "sell" rating in a research note on Saturday, August 8th. Needham & Company LLC dropped their price objective on shares of Oculis from $46.00 to $38.00 and set a "buy" rating for the company in a report on Monday, June 1st. Robert W. Baird dropped their price objective on shares of Oculis from $49.00 to $38.00 and set an "outperform" rating for the company in a report on Monday, June 1st. JPMorgan Chase & Co. reduced their target price on shares of Oculis from $23.00 to $20.00 and set an "overweight" rating on the stock in a research note on Friday, August 14th. Finally, Stifel Nicolaus decreased their target price on shares of Oculis from $50.00 to $40.00 and set a "buy" rating on the stock in a report on Monday, June 1st.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in OCS. Braidwell LP acquired a new position in shares of Oculis in the 2nd quarter worth approximately $11,570,000. Folketrygdfondet acquired a new stake in Oculis in the 4th quarter valued at approximately $3,651,000. Propel Bio Management LLC purchased a new stake in Oculis in the fourth quarter valued at approximately $3,452,000. NEXTBio Capital Management LP purchased a new stake in Oculis in the fourth quarter valued at approximately $2,991,000. Finally, Simplify Asset Management Inc. acquired a new position in Oculis during the fourth quarter worth $1,972,000. 22.30% of the stock is currently owned by institutional investors and hedge funds.

Oculis Stock Up 0.7%

OCS stock opened at $9.98 on Friday. The company has a current ratio of 8.35, a quick ratio of 8.35 and a debt-to-equity ratio of 0.01. The firm has a 50-day moving average of $12.10 and a two-hundred day moving average of $19.01. Oculis has a 12 month low of $9.65 and a 12 month high of $34.47. The company has a market cap of $578.64 million, a price-to-earnings ratio of -5.74 and a beta of 0.52.

Oculis (NASDAQ:OCS - Get Free Report) last issued its earnings results on Tuesday, June 30th. The company reported ($0.20) earnings per share for the quarter. Oculis had a negative return on equity of 42.61% and a negative net margin of 6,777.18%.The company had revenue of $0.38 million for the quarter. As a group, analysts forecast that Oculis will post -2.01 earnings per share for the current fiscal year.

Oculis Company Profile

Oculis is a clinical-stage biopharmaceutical company focused on developing ophthalmic therapies for eye diseases and vision loss. The company uses proprietary drug-delivery technologies designed to improve the delivery of treatments to specific tissues in the eye, with the goal of offering effective and convenient alternatives to injections or other invasive procedures.

Oculis' pipeline includes OCS-01, a topical eye-drop formulation of dexamethasone being developed for diabetic macular edema and inflammation following ocular surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.